scientific challenges, enabling researchers to make meaningful advances in their fields. Promega invites attendees of SFN 2024 to Booth #1316 to experience live demonstrations of the Glomax® Galaxy, showcasing its potential to transform research....
weight loss but also maintain the strength and energy they need for a healthy life." The study is set to start December 2024 at the nuHx headquarters in West Palm Beach and conclude May 2025 with published study results to follow. nuBioAge and its...
the Phase 1 trial will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in early November 2024. The Phase 1 trial is conducted in collaboration with Cleveland Clinic and is funded by a grant from the U.S. Department of...
and other bioactive substance innovations, showcased robust growth in its raw materials business in its newly released 2024 mid-year financial report. The company reported a total revenue of RMB 2.811 billion (～ USD 393.54 million) for the first...
will hold an advisory committee meeting with the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) on October 10, 2024 to evaluate the New Drug Application (NDA) for elamipretide, the first potential therapy for Barth syndrome. This...
of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. In 2024, Lunit acquired Volpara Health Technologies, setting the stage for unparalleled synergy and accuracy, particularly in breast...
for patients with cancer and diabetes, announced that its research collaborators were selected to present at the upcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The collaborators will present posters on positive...
Epidemiology, and End Results (SEER) Program, approximately 234,580 patients will be diagnosed with lung cancer in 2024, accounting for 11.7% of all new cancer cases, with approximately 125,070 expected patient deaths from prostate cancer in 2024,...
in a timely, safe and convenient way.” This year, the CDC recommends everyone ages 6 months and older receive updated 2024-2025 COVID-19 and flu vaccines, with rare exceptions. The CDC says that the concurrent administration of both vaccines is...
CVS Health® announced that the updated 2024-2025 COVID-19 vaccines and flu vaccines are available at CVS Pharmacy® and MinuteClinic® locations nationwide. Walk-ins are being accepted at CVS Pharmacy and the company's digital vaccine scheduler has...
Phase 1 clinical study of FTX-101 in healthy volunteers. The company anticipates the commencement of the study in Q4 2024. "The FDA's clearance of our IND marks an important achievement for Find, allowing us to proceed with our Phase 1 study of...
("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA) who undergo transcervical resection of...
Officer of Bavarian Nordic. The order from HERA will have no impact on the Company’s overall financial guidance for 2024 but brings the total value of secured contracts close to the lower level of the revenue guidance for the Public Preparedness...
company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius...
MTX-463, with approximately three quarters of the cohorts dosed, and completion of the trial expected by the end of 2024. Additionally, MTX-463 was granted orphan drug and fast track designations by the FDA, underscoring the potential of WISP1 to...
propionate ophthalmic suspension, 0.05% (APP13007) was approved by the U.S. Food and Drug Administration (FDA) on March 4, 2024. The licensing deal will include certain payments, including an upfront payment and milestone payments upon achievement...
to minimize systemic toxicity. The trial is anticipated to conclude by mid-2025, with top-line data expected year-end 2024. Dr. Michael Chancellor, Chief Medical Officer of Lipella added, “We have heard the urgency for new effective OLP therapies...
as a fixed-dose combination. The Company began enrolling patients in BROADWAY in January 2022 and in TANDEM in March 2024; completing enrollment of BROADWAY in July 2023, and TANDEM in July 2024. The Company also commenced the Phase 3 PREVAIL...
to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024. Innocan's LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and...
in patient recruitment. As a result, Teva and Sanofi now anticipate having topline results for both UC and CD in Q4 2024, and detailed results will be presented in a scientific forum in 2025. This adjustment replaces the previously planned interim...
